Analyst Price Target is $38.25
▲ +188.46% Upside Potential
This price target is based on 5 analysts offering 12 month price targets for MediWound in the last 3 months. The average price target is $38.25, with a high forecast of $56.00 and a low forecast of $23.00. The average price target represents a 188.46% upside from the last price of $13.26.
Current Consensus is
The current consensus among 5 contributing investment analysts is to buy stock in MediWound. This Buy consensus rating has held steady for over two years.
MediWound Ltd. is a biopharmaceutical company, which engages in the development, manufacture, and commercialization of products to address needs in the fields of severe burns, chronic wounds, and other hard-to-heal wounds. Its product is NexoBrid. The company was founded by Lior Rosenberg and Marian Gorecki in January 2000 and is headquartered in Yavne, Israel.